Palbocicilib
PreclinicalSmall molecule
Palbocicilib is one of 10 small molecule programs targeting Clear Cell Renal Carcinoma. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Clear Cell Renal Carcinoma
#DrugCompanyPhaseTrials
1Gleevec
NovartisApproved
Lenvima
EisaiApproved
Xtandi
AstellasApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Tarceva
OOSI Pharmaceuticals
Approved
Ixempra
RR-Pharm
Approved
Caprelsa
GGenzyme, a Sanofi Company
Approved
Inlyta
PPrism Pharmaceuticals
Approved
Sasanlimab
PfizerPreclinical
Palbocicilib
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer1 trial
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt
Completed·—·Phase 4·NCT07487129·206 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Palbocicilib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNational Cancer Institute (NCI)